Chimeric antigen receptor (CAR) T cell therapies offer a promising new therapeutic option for treating B cell malignancies, for instance relapsed or refractory diffuse large B cell lymphoma (DLBCL). However, patient access to this type of cellular …

The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 …

Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV+CHP, anti-CD30) is indicated as first-line treatment in the subgroup anaplastic …

Cutaneous lymphomas are a rare group of primary skin lymphoproliferative disorders, divided into T and B cell lymphomas. They differ substantially in clinical course and therapy. The two main subtypes of primary cutaneous T‑cell lymphomas include …

Established systemic treatment options for advanced thyroid cancer include the multityrosine kinase inhibitors lenvatinib and sorafenib for radioactive iodine refractory differentiated thyroid cancer (DTC) and vandetanib and cabozantinib for …

Compared to individuals without cancer, patients with a diagnosis of malignancy bear a higher risk of becoming infected with SARS-CoV‑2, suffer more frequently from disease-related complications, and are more likely to die due to coronavirus …

Immunotherapy was proven to be effective as first-line treatment for a subgroup of patients with gastroesophageal tumors and is already established as the standard of care. However, chemotherapy remains the backbone of treatment in both advanced …

This review summarizes current evidence of “theranostics” for patients with prostate cancer. Prostate-specific membrane antigen (PSMA) is a glycoprotein which can be labeled with positron-emitting tomographic (PET) tracers like fluorine-18 …

Over the past few decades, cure rates for Hodgkin’s lymphoma (HL) have consistently improved with advances in chemotherapy and radiation treatment. However, these therapies—whilst highly effective—may result in significant long-term toxicity with …

Diagnosis and decision-making in the treatment of breast cancer patients is vastly dependent on the exploration of biomarkers. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are long-standing biomarkers …

Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective …

Single agent immunotherapy is routinely used in the treatment of localised and advanced bladder cancer. Dual checkpoint inhibition with nivolumab (nivo)–ipilimumab (ipi) and durvalumab (durva)–tremelimumab (treme) shows encouraging activity in …

Radiotherapy (RT) remains an important modality in the modern treatment of lymphomas. In Hodgkin lymphoma (HL), its role is stage-dependent. In early stage favorable HL, RT is an essential component of combined treatment. In early unfavorable and …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by clonal expansion and accumulation of mature B‑lymphocytes in peripheral blood, bone marrow, and secondary lymphoid tissues [ 1 ]. CLL is highly heterogeneous where some …